

Press release

Hørsholm
20 August 2015

ALK to participate at the Goldman Sachs Biotech and Emerging Pharma Symposium in London

Page 1/1

ALK (ALKB:DC / OMX: ALK B / AKABY / AKBLF) today announced that the Company will be hosting investor meetings during the Goldman Sachs Biotech and Emerging Pharma Symposium to be held in London on Friday, 11 September 2015. Per Plotnikof, Vice President, Corporate Communications, Investor Relations and Strategic Planning, will give an overview of the Company and its key programmes.

ALK-Abelló A/S

For further information please contact:

Investor Relations:

Per Plotnikof, tel. +45 4574 7527, mobile +45 2261 2525

Janet Dally, tel. +1 609-466-0466

Press:

Jeppe Ilkjær, tel. +45 7877 4532, mobile +45 3050 2014

About ALK

ALK is a research-driven global pharmaceutical company focusing on allergy prevention, diagnosis and treatment. ALK is a world leader in allergy immunotherapy – a treatment of the underlying cause of allergy. The company has approximately 1,800 employees with subsidiaries, production facilities and distributors worldwide. ALK has entered into partnership agreements with MSD (known as Merck (NYSE: MRK) in the USA and Canada), Torii, Abbott and bioCSL to commercialise sublingual allergy immunotherapy tablets in North America, Japan, Russia, Australia and New Zealand, respectively. The company is headquartered in Hørsholm, Denmark, and listed on NASDAQ Copenhagen. Find more information at www.alk.net.